Cargando…
Letrozole in the extended adjuvant setting: MA.17
Relapse after completing adjuvant tamoxifen therapy is a persistent threat for women with hormone-responsive breast cancer. Third-generation aromatase inhibitors, such as letrozole, provide a new option for extended adjuvant hormonal therapy after 5 years of tamoxifen. MA.17 was conducted to determi...
| Autor principal: | |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Springer US
2007
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2001224/ https://www.ncbi.nlm.nih.gov/pubmed/17912635 http://dx.doi.org/10.1007/s10549-007-9698-1 |